In brief
- The professional guide hosted by ANSM is version 1 dated May 2026 and is distributed by ketamine authorization holders under its authority. This review read that PDF, not the patient guide or proof of two documents’ publication based solely on the URL.
- The document describes liver, urinary and dependence risks with repeated or prolonged use, without quantifying the probability increase for every patient.
- The criterion of at least 30% improvement at one month appears in the chronic-neuropathic-pain table. Other settings, including palliation, are treated separately; it is not a universal rule for every indication.
The professional guide on initiating and monitoring prolonged or repeated ketamine forms part of additional risk-minimization measures under ANSM authority. It is version 1 dated May 2026, although its URL includes a July path. This review did not verify a second guide’s publication date or inspect the 2023 historical alert.
What exactly is changing
The guide distinguishes perioperative pain, emergencies, brief painful care, chronic neuropathic pain and palliation; regimens are not interchangeable. It calls for baseline assessment, including prior dependence, and efficacy/tolerability monitoring. In chronic neuropathic pain, the 30% pain or quality-of-life improvement criterion is assessed at one month; palliation uses a different timetable. Repeated or prolonged use calls for liver, renal, urinary and misuse-risk monitoring. Liver-test changes require considering discontinuation; described severe injuries require stopping. These are context-specific clinical decisions, not instructions to adjust treatment independently.
Risks described in the professional guide
The document describes analgesic indications added since 2024 and risks with repeated or prolonged use, including urinary, renal, endocrine and liver injuries. It warns about tolerance, dependence and severe hepatic cases. This reading does not establish a quantitative trend in affected patients or explain why publication occurred on a particular date. A separate March 2026 ketamine framework for suicidal ideation was not reviewed.
What this implies
The guide’s value is in distinguishing treatment settings and monitoring harms and efficacy, without inferring an automatic expansion or restriction of access. Liver, urinary or dependence problems require clinical assessment; the document does not authorize extending analgesic protocols to other uses. Knowing which source and indication support a recommendation contributes to harm reduction. You can find more context on the drug on our page dedicated to ketamine.
Related previous coverage: Intravenous ketamine versus esketamine: differences in a major study.
Source
- ANSM. Instauration et suivi d’un traitement prolongé ou répété par kétamine — Guide à destination des professionnels de santé. Under ANSM authority, version 1, May 2026; PDF hosted in a July 8 path.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
